Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumor Necrosis Factor Inhibitor Treatment and Persistence Patterns in the Peripregnancy Period in Patients With Inflammatory Autoimmune Diseases.

ACR open rheumatology·2026

Same author

Correction: Randomization in the age of platform trials: unexplored challenges and some potential solutions.

BMC medical research methodology·2026

Same author

Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn.

NEJM evidence·2026

Same author

The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit-Risk, Autonomy, and Maternal-Fetal Interests.

American journal of perinatology·2025

Same author

Randomization in the age of platform trials: unexplored challenges and some potential solutions.

BMC medical research methodology·2025

Same author

Outcomes of Nononcology Accelerated Approvals.

JAMA·2025

Search research articles

Related Experiment Video

Updated: Oct 7, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Extrapolation as a Default Strategy in Pediatric Drug Development.

Margaret Gamalo¹, Christina Bucci-Rechtweg², Robert M Nelson³

¹Global Biometrics and Data Management - GPD I&I Statistics, 500 Arcola Rd, Collegeville, PA, 19426, USA. margaret.gamalo@pfizer.com.

Therapeutic Innovation & Regulatory Science

|January 10, 2022

Summary

Pediatric drug development should initially use extrapolation from adult data, acknowledging uncertainties. The level of extrapolation should adapt to disease context and tolerable risk for children.

Keywords:

Extrapolation Pediatric drug development Pediatric regulations Treatment landscape archetypes

More Related Videos

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Oct 7, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

Pharmacology
Pediatric Medicine
Drug Development

Background:

Pediatric drug development significantly lags behind adult drug development, creating a disparity in treatment options for children.
Existing strategies to address this gap include incentives, regulations, and innovative techniques like extrapolation of efficacy data from adult populations.

Purpose of the Study:

To advocate for the initial assumption of extrapolation in pediatric drug development programs, despite inherent uncertainties.
To propose a framework where the degree of extrapolation is a continuum, guided by the need to address uncertainties with pediatric evidence.

Main Methods:

Conceptual analysis and position paper based on existing literature and regulatory considerations.
Discussion of extrapolation as a strategy, emphasizing the continuum of uncertainty and the generation of pediatric evidence.

Main Results:

The paper posits that pediatric drug development should begin with an assumption of extrapolation.
The extent of extrapolation should be determined by the level of tolerable uncertainty, considering the risks of exposing children to new drugs.

Conclusions:

The strategy for extrapolation must be context-dependent, varying with disease severity and available therapies.
Integrating judgments about tolerable uncertainty into pediatric drug development archetypes can guide study design and consider simultaneous adult and adolescent development.